AgingResearch.NewsJoin free

Teriparatide mRNA-loaded exosomes

Teriparatide mRNA-loaded exosomes has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Oct 25, 2026: “Engineered bone-targeting particles reduced bone loss in mice”.

Intervention

1 paper studies it4 findingsUpdated

1 new paper in 30 daysSee all 1

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: Beijing Hospital Authority and 4 more
  • Animals1

What did studies of Teriparatide mRNA-loaded exosomes find?

4

Studies of Teriparatide mRNA-loaded exosomes measured 4 outcomes; the most studied are mineral apposition rate (1 study), trabecular microarchitecture (1) and bone tissue binding (1).

Mineral apposition rate

upin mice1

1 study

  1. Teriparatide mRNA-loaded exosomes increase mineral apposition rate in mice.

    “increased serum procollagen type I N-terminal propeptide levels, and enhanced the mineral apposition rate.”

    Animalsovariectomy-induced osteoporosisAsp6-functionalizedboneweekly administration

    Engineered bone-targeting particles reduced bone loss in mice

    Regenerative therapy

Trabecular microarchitecture

upin mice1

1 study

  1. Teriparatide mRNA-loaded exosomes improve trabecular microarchitecture in mice.

    “In ovariectomized mice, weekly administration of Asp6-Exo@TPTD improved trabecular microarchitecture”

    Animalsovariectomy-induced osteoporosisAsp6-functionalizedboneweekly administration

    Engineered bone-targeting particles reduced bone loss in mice

    Regenerative therapy

Bone tissue binding

upin mice1

1 study

  1. Teriparatide mRNA-loaded exosomes increase bone tissue binding in mice.

    “Asp6-Exo@TPTD exhibited greater binding to bone tissues than both unloaded Exo and non-targeted Exo@TPTD in vitro and ex vivo.”

    Animalsin vitro and ex vivo; compared with unloaded Exo and non-targeted Exo@TPTDAsp6-functionalizedbone

    Engineered bone-targeting particles reduced bone loss in mice

    Regenerative therapy

osteogenic differentiation

upin mouse cells1

1 study

  1. Teriparatide mRNA-loaded exosomes increase osteogenic differentiation in mouse cells.

    “enhanced CRE-dependent luciferase activity, osteogenic gene expression, alkaline phosphatase staining, and extracellular matrix mineralization.”

    CellsAsp6-functionalizedbone marrow mesenchymal stromal cell

    Engineered bone-targeting particles reduced bone loss in mice

    Regenerative therapy

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 11 paper in 12 months
Regenerative Therapy

Engineered bone-targeting particles reduced bone loss in mice

Weekly doses of particles carrying instructions for making the bone-building drug teriparatide improved spongy bone structure in a mouse model of osteoporosis.Weekly doses of particles carrying instructions for making the bone-building drug teriparatide improved spongy bone structure in a mouse model of osteoporosis.

Mouse studyBone loss
Paper

Related